

# Pascale Gaussem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6768872/publications.pdf>

Version: 2024-02-01

204  
papers

10,828  
citations

53660

45  
h-index

35952

97  
g-index

233  
all docs

233  
docs citations

233  
times ranked

16079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality due to hospital-acquired infection after cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 2131-2140.e3.	0.4	21
2	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€”From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	1.1	12
3	Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 93.	1.8	8
4	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. <i>Frontiers in Pharmacology</i> , 2022, 13, 878416.	1.6	2
5	Interleukin-8 Receptors CXCR1 and CXCR2 Are Not Expressed by Endothelial Colony-forming Cells. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 628-638.	1.7	0
6	Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 639-651.	1.7	18
7	Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVIDâ€”19: Insight From a French Multicenter Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e018624.	1.6	47
8	Role of oculocerebrorenal syndrome of Lowe (OCRL) protein in megakaryocyte maturation, platelet production and functions: a study in patients with Lowe syndrome. <i>British Journal of Haematology</i> , 2021, 192, 909-921.	1.2	6
9	D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 381-393.	0.7	31
10	Role of Membrane Lipid Rafts in MRP4 (ABCC4) Dependent Regulation of the cAMP Pathway in Blood Platelets. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1628-1636.	1.8	3
11	Anticoagulation in COVID-19: not strong for too long?. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100857.	0.6	9
12	Placental growth factor level in plasma predicts COVIDâ€”19 severity and inâ€”hospital mortality. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1823-1830.	1.9	28
13	Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 388.	1.5	26
14	Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device. <i>Anesthesiology</i> , 2021, 135, 246-257.	1.3	6
15	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. <i>Chest</i> , 2021, 159, 2417-2427.	0.4	54
16	Response. <i>Chest</i> , 2021, 160, e95-e96.	0.4	0
17	Induced forms of Î±2-macroglobulin neutralize heparin and direct oral anticoagulant effects. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 209-217.	3.6	4
18	Response. <i>Chest</i> , 2021, 160, e250.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Endoglin Is an Endothelial Housekeeper against Inflammation: Insight in ECFC-Related Permeability through LIMK/Cofilin Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8837.	1.8	3
20	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100919.	0.6	12
21	Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality. <i>Arthritis and Rheumatology</i> , 2021, 73, 1976-1985.	2.9	21
22	Reply to the authors of "Age-adjusted D-dimer cut-off levels to exclude venous thromboembolism in COVID-19 patients". <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100940.	0.6	0
23	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. <i>Angiogenesis</i> , 2021, 24, 505-517.	3.7	105
24	Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection. <i>Virology Journal</i> , 2021, 18, 211.	1.4	14
25	COMBINED PLATELET AND ERYTHROCYTE SALVAGE DURING ON-PUMP CARDIAC SURGERY USING SAME-STEP BY I-SEP AUTOTRANSFUSION DEVICE: INTERIM ANALYSIS OF THE I-TRANSEP STUDY. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, S19-S20.	0.6	0
26	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13079.	1.8	20
27	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. <i>European Journal of Pharmacology</i> , 2020, 866, 172798.	1.7	10
28	Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload. <i>Frontiers in Medicine</i> , 2020, 7, 586307.	1.2	34
29	Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet-Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation. <i>Journal of Clinical Medicine</i> , 2020, 9, 2361.	1.0	12
30	Autoregulation of Pulsatile Bioprosthetic Total Artificial Heart is Involved in Endothelial Homeostasis Preservation. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1313-1322.	1.8	7
31	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
32	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
33	No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19. <i>OncImmunology</i> , 2020, 9, 1857112.	2.1	4
34	Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 41, 415-429.	1.1	12
35	Angiopietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. <i>Angiogenesis</i> , 2020, 23, 611-620.	3.7	204
36	Curative anticoagulation prevents endothelial lesion in COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2391-2399.	1.9	66

#	ARTICLE	IF	CITATIONS
37	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. <i>Critical Care</i> , 2020, 24, 364.	2.5	118
38	Comparative In Vitro Study of Various $\beta_2$ -Adrenoreceptor Agonist Drugs for Ticagrelor Reversal. <i>Journal of Clinical Medicine</i> , 2020, 9, 809.	1.0	1
39	P2Y <sub>12</sub> Inhibition beyond Thrombosis: Effects on Inflammation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1391.	1.8	65
40	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020, 7, 599626.	1.2	11
41	Potential usefulness of activated charcoal (DOAC remove <sup>®</sup> ) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019, 184, 86-91.	0.8	30
42	DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. <i>FASEB Journal</i> , 2019, 33, 14270-14280.	0.2	52
43	Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. <i>Thrombosis Research</i> , 2019, 183, 159-162.	0.8	9
44	Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2019, 149, 46-51.	1.0	1
45	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1670-1682.	1.9	24
46	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. <i>European Journal of Anaesthesiology</i> , 2019, 36, 449-456.	0.7	22
47	Human Endothelial Colony Forming Cells Express Intracellular CD133 that Modulates their Vasculogenic Properties. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 590-600.	5.6	30
48	Interleukin-8 Release by Endothelial Colony-Forming Cells Isolated from Idiopathic Pulmonary Fibrosis Patients Might Contribute to Their Pathogenicity. , 2019, , .		0
49	Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing. <i>Blood Advances</i> , 2019, 3, 1702-1713.	2.5	14
50	Pain assessment and factors influencing pain during bone marrow aspiration: A prospective study. <i>PLoS ONE</i> , 2019, 14, e0221534.	1.1	12
51	Interleukin-8 release by endothelial colony-forming cells isolated from idiopathic pulmonary fibrosis patients might contribute to their pathogenicity. <i>Angiogenesis</i> , 2019, 22, 325-339.	3.7	23
52	Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension. <i>Pediatric Pulmonology</i> , 2019, 54, 66-72.	1.0	13
53	Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. <i>Haematologica</i> , 2018, 103, e226-e229.	1.7	15
54	Evidence that MRP4 is Only Partly Involved in S1P Secretion during Platelet Activation. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1116-1118.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Human endoglin as a potential new partner involved in platelet-endothelium interactions. Cellular and Molecular Life Sciences, 2018, 75, 1269-1284.	2.4	30
56	Egfl7 Represses the Vasculogenic Potential of Human Endothelial Progenitor Cells. Stem Cell Reviews and Reports, 2018, 14, 82-91.	5.6	26
57	Endothelial Microparticles are Associated to Pathogenesis of Idiopathic Pulmonary Fibrosis. Stem Cell Reviews and Reports, 2018, 14, 223-235.	5.6	31
58	Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report. TH Open, 2018, 02, e346-e349.	0.7	3
59	Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice. Stem Cell Reviews and Reports, 2018, 14, 812-822.	5.6	12
60	CD34+ Hematopoietic Stem Cell Count Is Predictive of Vascular Event Occurrence in Children with Sickle Cell Disease. Stem Cell Reviews and Reports, 2018, 14, 694-701.	5.6	1
61	Reduced endothelial thioredoxin-interacting protein protects arteries from damage induced by metabolic stress <i>in vivo</i> . FASEB Journal, 2018, 32, 3108-3118.	0.2	14
62	Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month. PLoS ONE, 2018, 13, e0200364.	1.1	7
63	<i>Beta-1,4-galactosyltransferase 2 c.909C&gt;T</i> gene variant is predictive of on-clopidogrel platelet reactivity. Pharmacogenomics, 2018, 19, 937-945.	0.6	3
64	FXa-Î±2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo. Thrombosis and Haemostasis, 2018, 118, 1535-1544.	1.8	7
65	Thrombin generation test: A reliable tool to evaluate the pharmacodynamics of vitamin K antagonist rodenticides in rats. Pesticide Biochemistry and Physiology, 2018, 146, 19-24.	1.6	3
66	Hemolytic anemia, iron deficiency and personal history of deep vein thrombosis: consider paroxysmal nocturnal hemoglobinuria. Sang Thrombose Vaisseaux, 2018, 30, 124-132.	0.1	0
67	The Carmat Bioprosthetic Total Artificial Heart Is Associated With Early Hemostatic Recovery and no Acquired von Willebrand Syndrome in Calves. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1595-1602.	0.6	26
68	Ticagrelor reversal: <i>in vitro</i> assessment of four haemostatic agents. Journal of Clinical Pathology, 2017, 70, 733-739.	1.0	14
69	Impaired thromboxane receptor dimerization reduces signaling efficiency: A potential mechanism for reduced platelet function <i>in vivo</i> . Biochemical Pharmacology, 2017, 124, 43-56.	2.0	12
70	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis, 2017, 15, 273-283.	1.9	111
71	Pulsed cavitation therapy using high-frequency ultrasound for the treatment of deep vein thrombosis in an <i>in vitro</i> model of human blood clot. Physics in Medicine and Biology, 2017, 62, 9282-9294.	1.6	5
72	Thioredoxin interacting protein endothelial deletion protects from alterations of angiogenic process in adult mice submitted to vascular accelerated aging. Archives of Cardiovascular Diseases Supplements, 2017, 9, 163.	0.0	0

#	ARTICLE	IF	CITATIONS
73	Human aortic valvular interstitial cells: evidence of vasculogenic potential during aortic valve stenosis. Archives of Cardiovascular Diseases Supplements, 2017, 9, 195.	0.0	0
74	Place de lâ€™Ã©puration extracorporelle de CO2 (ECCO2R) dans la prise en charge des pathologies respiratoires. Journal Europeen Des Urgences Et De Reanimation, 2017, 29, 345-353.	0.1	0
75	Hemolytic anemia, iron deficiency and personal history of deep vein thrombosis: consider paroxysmal nocturnal hemoglobinuria. Annales De Biologie Clinique, 2017, 75, 580-588.	0.2	3
76	The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation. European Journal of Anaesthesiology, 2016, 33, 361-367.	0.7	47
77	Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery. British Journal of Anaesthesia, 2016, 117, 749-757.	1.5	19
78	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. Pharmacological Research, 2016, 107, 381-389.	3.1	45
79	Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but Both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock. Circulation Research, 2016, 119, e110-26.	2.0	61
80	O130 : Endoglin is a new partner involved in platelet â€™ endothelium interactions: role in microvessel stability?. Archives of Cardiovascular Diseases Supplements, 2016, 8, 219.	0.0	0
81	Endoglin regulates mural cell adhesion in the circulatory system. Cellular and Molecular Life Sciences, 2016, 73, 1715-1739.	2.4	63
82	Leucocytes platelets co-aggregates remain elevated in patients with perfusion defects after pulmonary embolism. , 2016, , .		0
83	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood, 2015, 126, 1823-1830.	0.6	51
84	Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thrombosis and Haemostasis, 2015, 114, 735-747.	1.8	25
85	Bone-marrow-derived very small embryonic-like stem cells in patients with critical leg ischaemia: evidence of vasculogenic potential. Thrombosis and Haemostasis, 2015, 113, 1084-1094.	1.8	79
86	Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thrombosis and Haemostasis, 2015, 114, 78-86.	1.8	34
87	Multimodal assessment of nonâ€™specific hemostatic agents for apixaban reversal. Journal of Thrombosis and Haemostasis, 2015, 13, 426-436.	1.9	43
88	Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells. Intensive Care Medicine, 2015, 41, 231-238.	3.9	37
89	O260 : Endoglin in adhesion between endothelial and mural cells. Archives of Cardiovascular Diseases Supplements, 2015, 7, 147.	0.0	0
90	O304 : Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Archives of Cardiovascular Diseases Supplements, 2015, 7, 148.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Inefficacy of Platelet Transfusion to Reverse Ticagrelor. <i>New England Journal of Medicine</i> , 2015, 372, 196-197.	13.9	85
92	Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis-associated genes expression and leukocyte recruitment by a COX-2-dependent mechanism. <i>Angiogenesis</i> , 2015, 18, 347-359.	3.7	24
93	Cerebral haemorrhagic risk in children with sickle cell disease. <i>Developmental Medicine and Child Neurology</i> , 2015, 57, 187-193.	1.1	32
94	Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. , 2015, , .		2
95	Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling. , 2015, , .		0
96	Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1002-1013.	1.8	30
97	Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. <i>Angiogenesis</i> , 2014, 17, 603-616.	3.7	14
98	Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. <i>Pathologie Et Biologie</i> , 2014, 62, 391-394.	2.2	24
99	Imbalanced coagulation profile as a biomarker of migraine in children with sickle cell: Is this a link with cerebral ischemia?. <i>Journal of Pediatrics</i> , 2014, 165, 645-646.	0.9	2
100	Increase of angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. <i>Revue Des Maladies Respiratoires</i> , 2014, 31, 661.	1.7	0
101	Forearm ischemia decreases endothelial colony-forming cell angiogenic potential. <i>Cytotherapy</i> , 2014, 16, 213-224.	0.3	24
102	Impact of Aspirin and Clopidogrel Interruption on Platelet Function in Patients Undergoing Major Vascular Surgery. <i>PLoS ONE</i> , 2014, 9, e104491.	1.1	18
103	Evidence for Vasculogenic Potential and Endothelial Differentiation of Bone-Marrow-Derived Very Small Embryonic-like Stem Cells. <i>Blood</i> , 2014, 124, 5120-5120.	0.6	0
104	Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 687-699.	1.3	17
105	Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 661-671.	0.7	19
106	Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. <i>International Journal of Cardiology</i> , 2013, 168, 4228-4233.	0.8	96
107	Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. <i>Angiogenesis</i> , 2013, 16, 147-157.	3.7	52
108	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16402-16413.	1.8	1

#	ARTICLE	IF	CITATIONS
109	Platelet dysfunction associated with the novel Trp29Cys thromboxane $\text{AA}_2$ receptor variant. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 547-554.	1.9	24
110	Biphasic myosin II light chain activation during clot retraction. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1215-1222.	1.8	11
111	Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening. <i>PLoS ONE</i> , 2013, 8, e65114.	1.1	35
112	Angiogenic potential of BM MSCs derived from patients with critical leg ischemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 997-1000.	1.3	39
113	Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit. <i>British Journal of Anaesthesia</i> , 2012, 108, 586-593.	1.5	5
114	Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia. <i>Cytotherapy</i> , 2012, 14, 232-239.	0.3	31
115	Endogenous oestradiol as a positive correlate of plasma fibrinogen among older postmenopausal women: a population $\hat{C}$ -based study (the $\langle\text{sc}\rangle\text{T}\langle/\text{sc}\rangle\text{hree}\hat{C}\langle\text{sc}\rangle\text{C}\langle/\text{sc}\rangle\text{ity}$ cohort study). <i>Clinical Endocrinology</i> , 2012, 77, 905-910.	1.2	12
116	Antiplatelet and antithrombotic effect of F $\hat{C}$ f16618, a new thrombin proteinase $\hat{C}$ activated receptor $\hat{C}$ 1 (PAR1) antagonist. <i>British Journal of Pharmacology</i> , 2012, 165, 1827-1835.	2.7	16
117	The profibrotic cytokine transforming growth factor $\hat{C}$ 21 increases endothelial progenitor cell angiogenic properties. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 670-679.	1.9	36
118	Vascular endothelial growth factor, as compared with placental growth factor, is increased in severe sepsis but not in organ failure. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 974-976.	1.9	9
119	$\langle\text{i}\rangle\text{P2RY1}\langle/\text{i}\rangle$ and $\langle\text{i}\rangle\text{P2RY12}\langle/\text{i}\rangle$ polymorphisms and on $\hat{C}$ aspirin platelet reactivity in patients with coronary artery disease. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 473-483.	0.7	34
120	Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial activation. <i>Journal of Cardiology</i> , 2012, 59, 30-35.	0.8	11
121	High on-clopidogrel platelet reactivity: Genotyping Can help to optimize antiplatelet treatment. <i>Thrombosis Research</i> , 2011, 128, 92-95.	0.8	5
122	Haemostatic effects of a new combined oral contraceptive, norgestrel acetate/17 $\hat{C}$ 2-estradiol, compared with those of levonorgestrel/ethinyl estradiol. <i>Thrombosis and Haemostasis</i> , 2011, 105, 560-567.	1.8	77
123	Platelet receptor gain-of-function single nucleotide polymorphisms in carotid and vertebral stenosis patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 215-222.	1.0	2
124	Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. <i>Angiogenesis</i> , 2011, 14, 17-27.	3.7	52
125	Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 551-559.	1.1	111
126	Proton Pumps Inhibitors and Clopidogrel Interaction: Effect of Rabeprazole on the Anti-Platelet Function of Clopidogrel in Relation to CYP2C19 Genotype Status. A Prospective, Randomized, 3-way Crossover PK/PD Study in Healthy Subjects. <i>American Journal of Gastroenterology</i> , 2011, 106, S13.	0.2	0



#	ARTICLE	IF	CITATIONS
127	Les cellules endothéliales circulantes et les progéniteurs endothéliaux: produits de thérapie cellulaire ou biomarqueurs des pathologies vasculaires?. Sang Thrombose Vaisseaux, 2010, 22, 289-300.	0.1	0
128	Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. Thrombosis and Haemostasis, 2010, 104, 823-830.	1.8	11
129	Comparison of Endothelial Biomarkers According to Reversibility of Pulmonary Hypertension Secondary to Congenital Heart Disease. Pediatric Cardiology, 2010, 31, 657-662.	0.6	29
130	Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19 genotyped healthy subjects. Journal of Thrombosis and Haemostasis, 2010, 8, 610-613.	1.9	36
131	The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. Journal of Thrombosis and Haemostasis, 2010, 8, 2377-2384.	1.9	31
132	Angiogenèse, traitement héparinique et pathologies cancéreuses. Hematologie, 2010, 16, 129-142.	0.0	1
133	The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2544-2552.	1.1	60
134	Distinct patterns of circulating endothelial cells in pulmonary hypertension. European Respiratory Journal, 2010, 36, 1284-1293.	3.1	63
135	Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus, 2010, 19, 837-843.	0.8	27
136	Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1253-1262.	1.1	67
137	Les progéniteurs endothéliaux comme produit de thérapie cellulaire des pathologies cardiovasculaires?. Hematologie, 2010, 16, 198-207.	0.0	0
138	Endothelial progenitor cells are selectively mobilised immediately after coronary artery bypass grafting or valve surgery. Thrombosis and Haemostasis, 2009, 101, 983-985.	1.8	14
139	Déterminants génétiques de la réponse au clopidogrel. Hematologie, 2009, 15, 113-116.	0.0	0
140	Circulating Endothelial Cells. Circulation, 2009, 119, 374-381.	1.6	138
141	Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2009, 13, 2534-2546.	1.6	26
142	No influence of the VAMP8 rs1010 single nucleotide polymorphism on platelet functions <i>in vitro</i> . Journal of Cellular and Molecular Medicine, 2009, 13, 601-603.	1.6	3
143	Blood outgrowth endothelial cells from cord blood and peripheral blood: angiogenesis-related characteristics <i>in vitro</i> : a rebuttal. Journal of Thrombosis and Haemostasis, 2009, 7, 504-506.	1.9	8
144	Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. Journal of Thrombosis and Haemostasis, 2009, 7, 1972-1978.	1.9	41

#	ARTICLE	IF	CITATIONS
145	In Vitro Plasma-Induced Endothelial Oxidative Stress and Circulating Markers of Endothelial Dysfunction in Preeclampsia: An Observational Study. <i>Hypertension in Pregnancy</i> , 2009, 28, 212-223.	0.5	13
146	Endothelial progenitor cells are selectively mobilised immediately after coronary artery bypass grafting or valve surgery. <i>Thrombosis and Haemostasis</i> , 2009, 101, 983-5.	1.8	3
147	Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. <i>Modern Pathology</i> , 2008, 21, 837-846.	2.9	98
148	Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). <i>Nature Genetics</i> , 2008, 40, 284-286.	9.4	61
149	Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 975-986.	1.6	47
150	Purinergic receptor P2Y <sub>12</sub> , G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. <i>Atherosclerosis</i> , 2008, 197, 694-699.	0.4	40
151	No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease. <i>Thrombosis and Haemostasis</i> , 2008, 99, 970-972.	1.8	22
152	Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2137-2143.	1.1	101
153	Development of a Novel Immunoassay for the Assessment of Plasma Gas6 Concentrations and Their Variation with Hormonal Status. <i>Clinical Chemistry</i> , 2007, 53, 1808-1813.	1.5	23
154	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2153-2155.	1.9	117
155	Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances <i>in vitro</i> angiogenesis with up-regulation of integrin $\alpha_6$ . <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1149-1161.	1.6	85
156	Endothelial progenitor cells: Characterization, <i>in vitro</i> expansion, and prospects for autologous cell therapy. <i>Cell Biology and Toxicology</i> , 2007, 23, 223-239.	2.4	68
157	Haemorrhagic Complications of Vitamin K Antagonists in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 13-25.	1.3	29
158	Identification of functional polymorphisms of the thromboxane A <sub>2</sub> receptor gene in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2006, 96, 356-360.	1.8	28
159	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. <i>Blood</i> , 2006, 108, 2244-2247.	0.6	854
160	The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2051-2058.	1.9	56
161	Role of the P2Y <sub>12</sub> gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2096-2097.	1.9	36
162	PAR-1 activation has different effects on the angiogenic activity of endothelial progenitor cells derived from human adult and cord blood. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2729-2731.	1.9	30

#	ARTICLE	IF	CITATIONS
163	Physiological Plasma Gas6 Levels Do Not Influence Platelet Aggregation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, e22.	1.1	17
164	Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. <i>Platelets</i> , 2006, 17, 250-258.	1.1	65
165	PAR-1 Activation on Human Late Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4 System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2321-2327.	1.1	119
166	The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1437-1445.	1.9	67
167	P2Y1 gene polymorphism and ADP-induced platelet response. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2349-2350.	1.9	12
168	PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. <i>Platelets</i> , 2005, 16, 340-345.	1.1	48
169	The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2004, 91, 248-254.	1.8	34
170	Tissue factor expression and P2Y12 gene polymorphism. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1199-1200.	1.9	1
171	A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. <i>Blood</i> , 2004, 103, 1311-1318.	0.6	161
172	Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects. <i>Circulation</i> , 2003, 108, 989-995.	1.6	402
173	P2Y 12 H2 Haplotype Is Associated With Peripheral Arterial Disease. <i>Circulation</i> , 2003, 108, 2971-2973.	1.6	156
174	An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. <i>Blood</i> , 2003, 101, 1833-1840.	0.6	99
175	Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 147-154.	1.1	4
176	Delivery management in a woman with thrombocytopenia of the May-Hegglin anomaly type. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001, 99, 124-125.	0.5	8
177	Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the $\beta^3$ -carboxyglutamic acid-rich domain. <i>Biochemical Journal</i> , 2001, 360, 499-506.	1.7	15
178	Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the $\beta^3$ -carboxyglutamic acid-rich domain. <i>Biochemical Journal</i> , 2001, 360, 499.	1.7	10
179	Elderly Patients Treated with Tinzaparin (Innohep®) Administered once Daily (175 Anti-Xa IU/kg): Anti-Xa and Anti-IIa Activities over 10 Days. <i>Thrombosis and Haemostasis</i> , 2000, 84, 800-804.	1.8	124
180	Expression and Characterization of Recombinant Protein S with the Ser 460 Pro Mutation. <i>Thrombosis Research</i> , 2000, 100, 81-88.	0.8	15

#	ARTICLE	IF	CITATIONS
181	Characterization of cleaved plasma protein S with a monoclonal antibody-based assay. <i>Thrombosis and Haemostasis</i> , 2000, 84, 604-10.	1.8	3
182	Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. <i>Thrombosis and Haemostasis</i> , 2000, 84, 800-4.	1.8	55
183	Ruling Out Acute Deep Vein Thrombosis by ELISA Plasma D-Dimer Assay Versus Ultrasound in Inpatients More Than 70 Years Old. <i>Angiology</i> , 1999, 50, 873-882.	0.8	37
184	Identification of protein C epitopes altered during its nanoencapsulation. <i>The Protein Journal</i> , 1999, 18, 779-784.	1.1	2
185	Increase in expression and activity of thrombomodulin in term human syncytiotrophoblast microvilli. <i>Placenta</i> , 1998, 19, 261-268.	0.7	41
186	A monoclonal antibody recognizing the activation domain of protein C in its calcium-free conformation. <i>FEBS Letters</i> , 1998, 432, 94-97.	1.3	3
187	Venous Thrombosis in Older People: Prevalence of the Factor V Gene Mutation Q506. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 1545-1549.	1.3	17
188	RESPONSE TO DDAVP STIMULATION IN THIRTEEN PATIENTS WITH BUERGER'S DISEASE.. <i>Thrombosis Research</i> , 1997, 86, 85-87.	0.8	5
189	Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. <i>American Journal of Hematology</i> , 1995, 49, 109-114.	2.0	14
190	Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. <i>Blood</i> , 1995, 85, 130-138.	0.6	95
191	Human thrombin variable region 1, including E39, is involved in interactions with $\alpha_1$ -antitrypsin M358R and protein C. <i>FEBS Letters</i> , 1995, 365, 219-222.	1.3	1
192	Amino acids 225-235 of the protein C serine-protease domain are important for the interaction with the thrombin-thrombomodulin complex. <i>FEBS Letters</i> , 1995, 367, 153-157.	1.3	14
193	An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation. <i>Blood</i> , 1994, 84, 1843-1850.	0.6	18
194	A New Assay Based on Thrombin Generation Inhibition to Detect Both Protein C and Protein S Deficiencies in Plasma. <i>Thrombosis and Haemostasis</i> , 1994, 71, 331-338.	1.8	47
195	Influence of Six Mutations of the Protein C Gene on the Gla Domain Conformation and Calcium Affinity. <i>Thrombosis and Haemostasis</i> , 1994, 71, 748-754.	1.8	17
196	Neutralization of plasminogen activator inhibitor-1 (PAI-1) by activated protein C is species-dependent. <i>Fibrinolysis</i> , 1993, 7, 123-133.	0.5	3
197	Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. <i>Blood</i> , 1993, 82, 159-168.	0.6	34
198	Plasma levels of single-chain urokinase in the elderly. <i>Fibrinolysis</i> , 1992, 6, 66-67.	0.5	3

#	ARTICLE	IF	CITATIONS
199	The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1. BBA - Proteins and Proteomics, 1991, 1079, 321-329.	2.1	7
200	Development of an internal standard for plasminogen activator inhibitor-1 PAI-1 and its use in a simplified assay for measuring pai-1 activity in human plasma. Fibrinolysis, 1990, 4, 127-129.	0.5	2
201	The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods. Fibrinolysis, 1990, 4, 177-181.	0.5	6
202	A Plasma Clot Lysis Assay Based on the Release of Fibrin Degradation Products: Application to the Diagnosis of Hypofibrinolytic States. Thrombosis and Haemostasis, 1990, 63, 076-081.	1.8	2
203	Functional identification of t-PA in crude and purified systems. Thrombosis Research, 1988, 50, 123-130.	0.8	0
204	Functional identification of t-PA in crude and purified systems. Thrombosis Research, 1988, 49, 123-130.	0.8	2